The Market Reports

Synopsis

The global market for DNA Sequencing was estimated to be worth US$ 23728 million in 2024 and is forecast to a readjusted size of US$ 69863 million by 2031 with a CAGR of 16.4% during the forecast period 2025-2031.

DNA Sequencing is a core technology used to determine the order of nucleotides (A, T, C, G) in a DNA molecule. By comprehensively analyzing genomes, this technology reveals individual genetic variations and disease-related mutations. The dominant platforms include Next-Generation Sequencing (NGS) and Third-Generation Sequencing (TGS), which offer high throughput, precision, and scalability. DNA sequencing is widely applied in disease diagnosis, cancer precision medicine, reproductive health, microbiology, agricultural breeding, and forensic science. It has become a foundational driver for the advancement of precision medicine, biopharmaceutical R&D, and the bioinformatics industry, profoundly transforming the research paradigm in life sciences.

With growing global demand for precision medicine, biodiversity research, and personalized healthcare. Key drivers include increased government funding in public health and disease prevention, dramatic reductions in sequencing costs, enhanced interpretation efficiency enabled by AI and cloud computing, and the rapid adoption of high-growth applications such as liquid biopsy and non-invasive prenatal testing (NIPT). Regulatory environments are also maturing, facilitating faster commercialization.

Despite continuous technological advancements, the DNA sequencing industry faces notable challenges, including raw material price volatility, data security compliance, IP barriers, and inconsistencies in clinical interpretation. High-end sequencing platforms heavily depend on stable supply chains, with critical components such as chips and enzymes monopolized by a few suppliers, making them vulnerable to geopolitical disruptions. In developed regions, stricter legislation on genetic privacy introduces compliance burdens for global service providers. Emerging markets like China also face constraints in terms of reimbursement systems and clinical adoption pathways for advanced testing services.

In high-value application areas like cancer screening, rare disease diagnostics, birth defect prevention, and reproductive health, downstream demand is shifting toward customized solutions tailored to specific diseases. Demand for whole-genome and single-cell sequencing is also rising rapidly among pharmaceutical companies and CROs, driving convergence with AI-enabled diagnostics and CDx platforms. National regulations on human genetic resource management are propelling local database initiatives and ecosystem upgrades. In the foreseeable future, sequencing data will become the foundation of medical decision-making and drug discovery, fueling new business models such as Data-as-a-Service (DaaS) and genomic cloud platforms.

This report aims to provide a comprehensive presentation of the global market for DNA Sequencing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of DNA Sequencing by region & country, by Type, and by Application.

The DNA Sequencing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DNA Sequencing.

Market Segmentation

By Company

• Illumina
• Thermo Fisher Scientific
• Eurofins Scientific
• BGI
• Natera
• Berry Genomics
• Roche
• Novo Gene
• MGI-Tech
• LabCorp
• Pacific Biosciences
• Azenta Life Sciences
• Oxford Nanopore
• Macrogen

Segment by Type

• First Generation DNA Sequencing
• Second Generation DNA Sequencing
• Third Generation DNA Sequencing

Segment by Application

• Academic Research
• Clinical Research
• Hospitals and Clinics
• Pharmaceuticals and Biotechnology
• Other

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.